503 related articles for article (PubMed ID: 20015040)
21. Small molecule 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
Sun D; Wang M; Wang Z
Curr Top Med Chem; 2011; 11(12):1464-75. PubMed ID: 21510838
[TBL] [Abstract][Full Text] [Related]
22. 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action.
Seckl JR
Curr Opin Pharmacol; 2004 Dec; 4(6):597-602. PubMed ID: 15525550
[TBL] [Abstract][Full Text] [Related]
23. Genistein inhibits glucocorticoid amplification in adipose tissue by suppression of 11β-hydroxysteroid dehydrogenase type 1.
Tagawa N; Kubota S; Kobayashi Y; Kato I
Steroids; 2015 Jan; 93():77-86. PubMed ID: 25447798
[TBL] [Abstract][Full Text] [Related]
24. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of Novel 2-(Isopropylamino)thiazol-4(5
Kupczyk D; Studzińska R; Bilski R; Baumgart S; Kołodziejska R; Woźniak A
Molecules; 2020 Sep; 25(18):. PubMed ID: 32942682
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
27. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y
Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
Stanetty C; Czollner L; Koller I; Shah P; Gaware R; Cunha TD; Odermatt A; Jordis U; Kosma P; Classen-Houben D
Bioorg Med Chem; 2010 Nov; 18(21):7522-41. PubMed ID: 20851614
[TBL] [Abstract][Full Text] [Related]
29. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of 11β-HSD1 by LG13 improves glucose metabolism in type 2 diabetic mice.
Zhao L; Pan Y; Peng K; Wang Z; Li J; Li D; Tong C; Wang Y; Liang G
J Mol Endocrinol; 2015 Oct; 55(2):119-31. PubMed ID: 26220348
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological evaluation of adipose dysfunction via 11β-hydroxysteroid dehydrogenase type 1 in the development of diabetes in diet-induced obese mice with cortisone pellet implantation.
Akiyama N; Akiyama Y; Kato H; Kuroda T; Ono T; Imagawa K; Asakura K; Shinosaki T; Murayama T; Hanasaki K
J Pharmacol Exp Ther; 2014 Apr; 349(1):66-74. PubMed ID: 24511146
[TBL] [Abstract][Full Text] [Related]
32. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
[TBL] [Abstract][Full Text] [Related]
33. Green tea and one of its constituents, Epigallocatechine-3-gallate, are potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.
Hintzpeter J; Stapelfeld C; Loerz C; Martin HJ; Maser E
PLoS One; 2014; 9(1):e84468. PubMed ID: 24404164
[TBL] [Abstract][Full Text] [Related]
34. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
35. Modulation of glucocorticoid action and the treatment of type-2 diabetes.
Tomlinson JW; Stewart PM
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):607-19. PubMed ID: 18054738
[TBL] [Abstract][Full Text] [Related]
36. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
37. Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes.
Hale C; Wang M
Mini Rev Med Chem; 2008 Jun; 8(7):702-10. PubMed ID: 18537725
[TBL] [Abstract][Full Text] [Related]
38. Carbonyl reduction of triadimefon by human and rodent 11β-hydroxysteroid dehydrogenase 1.
Meyer A; Vuorinen A; Zielinska AE; Da Cunha T; Strajhar P; Lavery GG; Schuster D; Odermatt A
Biochem Pharmacol; 2013 May; 85(9):1370-8. PubMed ID: 23419873
[TBL] [Abstract][Full Text] [Related]
39. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
40. 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction.
Wu L; Qi H; Zhong Y; Lv S; Yu J; Liu J; Wang L; Bi J; Kong X; Di W; Zha J; Liu F; Ding G
Endocr J; 2013; 60(9):1047-58. PubMed ID: 23759754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
